KRT18 and metabolic dysfunction-associated steatohepatitis: Although the AASLD guidelines published in 2012 [13] do not recommend the use of cytokeratin-18 in routine clinical practice, a recent meta-analysis on more than 800 patients in 10 studies [30] concluded that both cytokeratin-18 fragments and total cytokeratin-18 have a clinically meaningful benefit in the non-invasive diagnosing of NASH.